Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fampridine-SR in Multiple Sclerosis (MS-F204)
NCT00483652Phase 3Completed
- Sponsor
- Acorda Therapeutics
- Start
- May 2007
- Primary completion
- Feb 2008
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of dalfampridine in multiple sclerosis (MS), sponsored by Acorda Therapeutics. Started May 2007; status: completed.
02
Drugs
dalfampridine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT00483652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00483652.